地中海の食習慣に従うことは,クローン病患者の生化学的寛解と関連している
Lior Mor-Sasson1, Chen Sarbagili-Shabat2, Shiri Sherf-Dagan3
1Department of Nutrition Sciences, School of Health Sciences, Ariel University, Ariel, Israel.
Clinical nutrition (Edinburgh, Scotland)
|August 22, 2025
まとめ
地中海食 (MD) に従うことは,クロン病患者の内カルプロテクチン (FC) 値の低下と関連している.
科学分野:
- 胃腸内科と栄養
- 炎症性腸疾患の研究
- ダイエット 介入
背景:
- 地中海食 (MD) は,クローン病 (CD) の患者にとって有望である.
- 活動中のCDではMDの遵守は困難です.
- この研究では,CD寛解におけるMDアデンスと糞便カルプロテクチン (FC) の変化を調査しています.
研究 の 目的:
- 地中海食 (MD) に従うことと糞便のカルプロテクチン (FC) レベルの変化との関連を評価する.
- クローン病 (Crohn' s Disease) の臨床的および生化学的寛解における患者におけるMDの遵守を評価する.
主な方法:
- クリニカルおよび生化学的寛解 (HBI < 5,FC < 250 μg/ g) の96人のクローン病 (CD) 患者による前向きなコホート研究.
- FC ≤150μg/gとして定義される深い生化学的寛解
- イスラエルの地中海ダイエットスクリーナー (I-MEDAS) を使用してMDの遵守を評価し,中位値はカットオフとして評価した.
主要な成果:
- ベースラインのMD遵守は,3ヶ月で深い寛解率 (87. 5% vs. 64. 3%) と関連していました.
- 時間が経つにつれMDの順守が低下することが観察されました.
- FC値の変化は,有害なMD成分への適合と負の相関関係にある (r = - 0. 340,p = 0. 006).
結論:
- 地中海ダイエット (MD) の遵守は,発症初期と介入後3ヶ月で内カルプロテクチン (FC) の低値と相関しています.
- クローン病 (Crohn's Disease,CD) の寛解を維持する上でMDの長期的影響を調査するには,さらなる研究が必要である.
関連する概念動画
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:30Inflammatory Bowel Disease II: Crohn's Disease
382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382